Nahit Topaloglu
Nahit Topaloglu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Celalettin Eroğlu
Department of Radiation Oncology, Erciyes University Medical Faculty, Kayseri, Turkey
1 shared publication - Erdem Sahin
Department of Obstetrics and Gynecology, Erciyes University Medicine Faculty, Kayseri, Turkey
1 shared publication - Erol Karakas
Department of Obstetrics and Gynecology, Op. Dr. Erol Karakaş Gynecology And Obstetrics Clinic, Kayseri, Turkey
1 shared publication - Hatice Basaran Goksen
Department of Radiation Oncology, Kayseri City Education and Research Hospital, Kayseri, Turkey
1 shared publication - Hulya Akgun
Department of Pathology, Erciyes University Medical Faculty, Kayseri, Turkey
1 shared publication - Mehmet Mete Kirlangic
Department of Obstetrics and Gynecology , University of Health Sciences Turkey, Kartal Doctor Lütfi Kırdar City Hospital , Istanbul , Türkiye
1 shared publication
Latest Publications
- Open Access
- 29 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 27653
The prognostic importance of neuronatin positivity as immunohistochemical in patients with lung adenocarcinoma in the development of brain metastasis
To search the prognostic significance of the neuronatin (NNAT) protein diagnosed with lung adenocarcinoma in the occurence of brain metastasis. Sixty-six of 200 patients diagnosed with lung adenocarcinoma who received radiotherapy (RT) between 2014 and 2017 were included in the study. A total of 66 patients, 33 (50%) with brain pathology and 33 (50%) with lung pathology, were analyzed retrospectively. Furthermore NNAT-immune-reactivity score (IRS) and nuclear positivity were analyzed in terms of pathological factors. In 33 cases where primary tumor pathology was studied, a statistically borderline significant effect was found for the N stage and a statistically significant effect on overall survival (OS) for nuclear positivity. While OS was 7.6 months in nucleus positively stained (PNS) cases, it was 24.4 months in negatively stained (NNS) cases. While the survival of NNAT-IRS positive cases without cranial metastasis was 20.7 months, the survival of the negative group without cranial metastasis was 61.2 months. The survival of cases with PNS without cranial metastasis was 7.1 months, while the survival of cases with NNS results without cranial metastasis was 52.1 months. In cases where intracranial pathologies, the number of intracranial metastases and the presence of extracranial metastases were found to be statistically significant independent factors (p < 0.001, p < 0.001). With NNAT study in initial pathological tissues of patients diagnosed with lung adenocarcinoma, especially nuclear positivity and NNAT-IRS positivity, a strong prediction can be made about the occurrence of brain metastasis.
- 29 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 27653
Open AccessThe prognostic importance of neuronatin positivity as immunohistochemical in patients with lung adenocarcinoma in the development of brain metastasis
To search the prognostic significance of the neuronatin (NNAT) protein diagnosed with lung adenocarcinoma in the occurence of brain metastasis. Sixty-six of 200 patients diagnosed with lung adenocarcinoma who received radiotherapy (RT) between 2014 and 2017 were included in the study. A total of 66 patients, 33 (50%) with brain pathology and 33 (50%) with lung pathology, were analyzed retrospectively. Furthermore NNAT-immune-reactivity score (IRS) and nuclear positivity were analyzed in terms of pathological factors. In 33 cases where primary tumor pathology was studied, a statistically borderline significant effect was found for the N stage and a statistically significant effect on overall survival (OS) for nuclear positivity. While OS was 7.6 months in nucleus positively stained (PNS) cases, it was 24.4 months in negatively stained (NNS) cases. While the survival of NNAT-IRS positive cases without cranial metastasis was 20.7 months, the survival of the negative group without cranial metastasis was 61.2 months. The survival of cases with PNS without cranial metastasis was 7.1 months, while the survival of cases with NNS results without cranial metastasis was 52.1 months. In cases where intracranial pathologies, the number of intracranial metastases and the presence of extracranial metastases were found to be statistically significant independent factors (p < 0.001, p < 0.001). With NNAT study in initial pathological tissues of patients diagnosed with lung adenocarcinoma, especially nuclear positivity and NNAT-IRS positivity, a strong prediction can be made about the occurrence of brain metastasis.
- Open Access
- 30 December 2021
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 46 (4) , 1401-1408
Clinicopathological importance of survivin immunoexpression in reproductive age patients with serous borderline ovarian tumors
Purpose: The aim of the present study was to evaluate survivin immunoexpression and the clinicopathologic correlations in serous borderline ovarian tumors (BOT) patients ≤ 40 years old. Materials and Methods: A total of 36 BOT cases were evaluated. After excluding the mucinous type and patients over 40 years of age, 20 serous BOT cases meeting the criteria were included. A similar number of benign ovarian cysts and 20 serous malign ovarian tumors were randomly included as the control group. The patients were then staged based on their surgical findings and 2014 FIGO criteria, and their histological tumor types obtained from pathological specimens were determined using WHO criteria. The survivin levels in the specimens were analyzed using immunohistochemical assays. Results: Positive survivin expression was detected in 10% of benign tumors, 100% of serous BOTs, and 100% of serous malign ovarian tumors. Mean survivin immunoreactivity was statistically similar between groups and it was found to be significantly higher in both groups compared to the control group. Survivin expression was positively correlated with FIGO stage, tumor grade, microinvasion, and micropapillary pattern. Conclusion: Survivin immunoexpression is correlated with the malignancy potential of serous BOTs, and that survivin immune expression may be a histopathological marker that will help in making a decision on fertility-sparing surgery and follow upin young patients.
- 30 December 2021
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 46 (4) , 1401-1408
Open AccessClinicopathological importance of survivin immunoexpression in reproductive age patients with serous borderline ovarian tumors
Purpose: The aim of the present study was to evaluate survivin immunoexpression and the clinicopathologic correlations in serous borderline ovarian tumors (BOT) patients ≤ 40 years old. Materials and Methods: A total of 36 BOT cases were evaluated. After excluding the mucinous type and patients over 40 years of age, 20 serous BOT cases meeting the criteria were included. A similar number of benign ovarian cysts and 20 serous malign ovarian tumors were randomly included as the control group. The patients were then staged based on their surgical findings and 2014 FIGO criteria, and their histological tumor types obtained from pathological specimens were determined using WHO criteria. The survivin levels in the specimens were analyzed using immunohistochemical assays. Results: Positive survivin expression was detected in 10% of benign tumors, 100% of serous BOTs, and 100% of serous malign ovarian tumors. Mean survivin immunoreactivity was statistically similar between groups and it was found to be significantly higher in both groups compared to the control group. Survivin expression was positively correlated with FIGO stage, tumor grade, microinvasion, and micropapillary pattern. Conclusion: Survivin immunoexpression is correlated with the malignancy potential of serous BOTs, and that survivin immune expression may be a histopathological marker that will help in making a decision on fertility-sparing surgery and follow upin young patients.